U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

President Trump recently warned big drugmakers that a pharmaceutical "tariff wall" is coming. Investors often view ...

LLY is bullish in weekly sequence from all time low. It favors rally in (V) after double correction ended at $677.09 low in ...

Eli Lilly (NYSE:LLY) recently experienced a slight decline in share price of 1.38% over the last month. This period coincided ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.